Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H23NO3.C4H6O4 |
Molecular Weight | 431.4789 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCC(O)=O.CCOC1=C(O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3)C=CC=C1
InChI
InChIKey=YXZTUOWIYOESGT-HLRBRJAUSA-N
InChI=1S/C19H23NO3.C4H6O4/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18;5-3(6)1-2-4(7)8/h3-11,18-20H,2,12-14H2,1H3;1-2H2,(H,5,6)(H,7,8)/t18-,19-;/m0./s1
Molecular Formula | C4H6O4 |
Molecular Weight | 118.088 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C19H23NO3 |
Molecular Weight | 313.3908 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Esreboxetine (PNU-165442G) is the (S,S)-(+)-enantiomer of antidepressant reboxetine, a selective norepinephrine reuptake inhibitor. The (S,S)-enantiomer is a more potent inhibitor of norepinephrine transporter than (R,R)-enantiomer. Esreboxetine was being developed by Pfizer, primarily for the treatment of fibromyalgia.
CNS Activity
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. | 1995 Aug |
|
Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. | 1997 Apr |
|
Reboxetine for the treatment of patients with Cocaine Dependence Disorder. | 2005 Apr |
|
[Advanced mesh implants for vaginal pelvic floor reconstruction: report of 100 prolift operations]. | 2007 Dec |
|
Transvaginal repair of genital prolapse: preliminary results of a new tension-free vaginal mesh (Prolift technique)--a case series multicentric study. | 2007 Jul |
|
Pelvic arterial embolization in the setting of acute hemorrhage as a result of the anterior Prolift procedure. | 2007 Jul |
|
Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril. | 2008 |
|
Hormonal influences on cardiovascular norepinephrine transporter responses in healthy women. | 2008 Apr |
|
One-year anatomic and quality-of-life outcomes after the Prolift procedure for treatment of posthysterectomy prolapse. | 2008 Dec |
|
Vaginal repair of cystocele with anterior wall mesh via transobturator route: efficacy and complications with up to 3-year followup. | 2009 |
|
The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression. | 2009 |
|
Short term impact on female sexual function of pelvic floor reconstruction with the Prolift procedure. | 2009 Nov |
|
Transvaginal mesh repair of anterior and posterior vaginal wall prolapse: a clinical and ultrasonographic study. | 2010 Apr |
|
Anatomical and functional outcomes of posterior intravaginal slingplasty for the treatment of vaginal vault or uterine prolapse: a prospective, multicenter study. | 2010 Mar |
|
Optimal primary minimally invasive treatment for patients with stress urinary incontinence and symptomatic pelvic organ prolapse: tension free slings with colporrhaphy, or Prolift with the tension free midurethral sling? | 2010 May |
|
Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. | 2010 Oct 12 |
|
Now or later...Does timing of a midurethral sling in relation to transvaginal prolapse repair affect continence outcomes at 1 year? | 2010 Sep |
|
Vaginal hysterectomy at the time of transvaginal mesh placement. | 2010 Sep |
|
Antidepressant drugs transactivate TrkB neurotrophin receptors in the adult rodent brain independently of BDNF and monoamine transporter blockade. | 2011 |
|
Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152). | 2011 Oct 13 |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:31:02 GMT 2025
by
admin
on
Mon Mar 31 18:31:02 GMT 2025
|
Record UNII |
XQO13W6OCH
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Mon Mar 31 18:31:02 GMT 2025 , Edited by admin on Mon Mar 31 18:31:02 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000127897
Created by
admin on Mon Mar 31 18:31:02 GMT 2025 , Edited by admin on Mon Mar 31 18:31:02 GMT 2025
|
PRIMARY | |||
|
SUB34044
Created by
admin on Mon Mar 31 18:31:02 GMT 2025 , Edited by admin on Mon Mar 31 18:31:02 GMT 2025
|
PRIMARY | |||
|
DTXSID10979793
Created by
admin on Mon Mar 31 18:31:02 GMT 2025 , Edited by admin on Mon Mar 31 18:31:02 GMT 2025
|
PRIMARY | |||
|
TT-90
Created by
admin on Mon Mar 31 18:31:02 GMT 2025 , Edited by admin on Mon Mar 31 18:31:02 GMT 2025
|
PRIMARY | |||
|
CHEMBL180101
Created by
admin on Mon Mar 31 18:31:02 GMT 2025 , Edited by admin on Mon Mar 31 18:31:02 GMT 2025
|
PRIMARY | |||
|
24754241
Created by
admin on Mon Mar 31 18:31:02 GMT 2025 , Edited by admin on Mon Mar 31 18:31:02 GMT 2025
|
PRIMARY | |||
|
635724-55-9
Created by
admin on Mon Mar 31 18:31:02 GMT 2025 , Edited by admin on Mon Mar 31 18:31:02 GMT 2025
|
PRIMARY | |||
|
XQO13W6OCH
Created by
admin on Mon Mar 31 18:31:02 GMT 2025 , Edited by admin on Mon Mar 31 18:31:02 GMT 2025
|
PRIMARY | |||
|
C87613
Created by
admin on Mon Mar 31 18:31:02 GMT 2025 , Edited by admin on Mon Mar 31 18:31:02 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|